FDA Eyes Changes To IRB Adverse Event Reporting; March Meeting Planned
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers and other stakeholders will have an opportunity next month to discuss ways that reporting adverse events to institutional review boards can be improved